Everest to Buy Hasten Bio Singapore Unit for $150M

Everest Medicines Ltd. agreed to acquire the Singapore-based commercial unit of Hasten Biopharmaceuticals (Asia) Ltd. for $150 million up front. The deal grants Everest market authorization holder rights to 14 marketed products originally developed by Takeda Pharmaceutical Co. Ltd.

The excerpt also references a $250 million deal value, but the stated upfront consideration is $150 million. The transaction is announced and subject to standard closing processes for commercial-unit transfers.